Levothyroxine Bioequivalence Studies Need Thyroid-Free Baseline – Abbott
Executive Summary
FDA should require generic companies to conduct levothyroxine bioequivalence studies in athyreotic patients as a condition of ANDA approval, Abbott suggests in an Aug. 25 citizen petition
You may also be interested in...
Abbott Predicts Arthritis Therapy Humira Will Top $1 Bil. In 2005
Abbott predicts Humira (adalimumab) sales will top $1 bil. worldwide in 2005
Abbott Predicts Arthritis Therapy Humira Will Top $1 Bil. In 2005
Abbott predicts Humira (adalimumab) sales will top $1 bil. worldwide in 2005
Levothyroxine Review Standards Should Be Same For ANDAs, Brands – Petition
Levothyroxine generics should be held to the same review standards as their 505(b)(2) counterparts, Unithroid manufacturer Jerome Stevens maintained in a 1citizen petition to FDA